Latest Affinity Asset Advisors, LLC Stock Portfolio
Affinity Asset Advisors, LLC Performance:
2025 Q3: 18.44%YTD: 13.62%2024: 13.87%
Performance for 2025 Q3 is 18.44%, and YTD is 13.62%, and 2024 is 13.87%.
About Affinity Asset Advisors, LLC and 13F Hedge Fund Stock Holdings
Affinity Asset Advisors, LLC is a hedge fund based in NEW YORK, NY. On 29-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $237.6 Millions. In it's latest 13F Holdings report, Affinity Asset Advisors, LLC reported an equity portfolio of $1.1 Billions as of 30 Sep, 2025.
The top stock holdings of Affinity Asset Advisors, LLC are VRNA, INSM, SPY. The fund has invested 5.8% of it's portfolio in VERONA PHARMA PLC and 5.6% of portfolio in INSMED INC.
The fund managers got completely rid off BLUEPRINT MEDICINES CORP (BPMC), INOZYME PHARMA INC (INZY) and AXSOME THERAPEUTICS INC (AXSM) stocks. They significantly reduced their stock positions in CRESCENT BIOPHARMA INC., BRIDGEBIO PHARMA INC (BBIO) and CRINETICS PHARMACEUTICALS IN (CRNX). Affinity Asset Advisors, LLC opened new stock positions in SPDR S&P 500 ETF TR (SPY), CYTOKINETICS INC (CYTK) and SOLENO THERAPEUTICS INC (SLNO). The fund showed a lot of confidence in some stocks as they added substantially to TAYSHA GENE THERAPIES INC (TSHA), ZURA BIO LTD and MERUS N V (MRUS).
The top stock holdings of Affinity Asset Advisors, LLC are VRNA, INSM, SPY. The fund has invested 5.8% of it's portfolio in VERONA PHARMA PLC and 5.6% of portfolio in INSMED INC.
The fund managers got completely rid off BLUEPRINT MEDICINES CORP (BPMC), INOZYME PHARMA INC (INZY) and AXSOME THERAPEUTICS INC (AXSM) stocks. They significantly reduced their stock positions in CRESCENT BIOPHARMA INC., BRIDGEBIO PHARMA INC (BBIO) and CRINETICS PHARMACEUTICALS IN (CRNX). Affinity Asset Advisors, LLC opened new stock positions in SPDR S&P 500 ETF TR (SPY), CYTOKINETICS INC (CYTK) and SOLENO THERAPEUTICS INC (SLNO). The fund showed a lot of confidence in some stocks as they added substantially to TAYSHA GENE THERAPIES INC (TSHA), ZURA BIO LTD and MERUS N V (MRUS).
Affinity Asset Advisors, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Affinity Asset Advisors, LLC made a return of 18.44% in the last quarter. In trailing 12 months, it's portfolio return was 13.02%.
New Buys
| Ticker | $ Bought |
|---|---|
| spdr s&p 500 etf tr | 56,285,500 |
| cytokinetics inc | 19,236,000 |
| soleno therapeutics inc | 13,520,000 |
| dianthus therapeutics inc | 10,313,600 |
| celldex therapeutics inc new | 7,761,000 |
| tarsus pharmaceuticals inc | 7,428,750 |
| immunovant inc | 4,836,000 |
| revolution medicines inc | 4,670,000 |
New stocks bought by Affinity Asset Advisors, LLC
Additions
| Ticker | % Inc. |
|---|---|
| taysha gene therapies inc | 1,400 |
| zura bio ltd | 470 |
| merus n v | 308 |
| ovid therapeutics inc | 296 |
| abivax sa | 260 |
| savara inc | 200 |
| spyre therapeutics inc | 133 |
| uniqure nv | 122 |
Additions to existing portfolio by Affinity Asset Advisors, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| crescent biopharma inc. | -93.57 |
| perspective therapeutics inc | -71.43 |
| bridgebio pharma inc | -56.67 |
| crinetics pharmaceuticals in | -50.74 |
| protagonist therapeutics inc | -49.86 |
| travere therapeutics inc | -48.45 |
| vera therapeutics inc | -44.34 |
| autolus therapeutics plc | -42.53 |
Affinity Asset Advisors, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| inozyme pharma inc | -6,997,440 |
| nkarta inc | -1,328,000 |
| third harmonic bio inc | -2,009,100 |
| onkure therapeutics inc | -831,696 |
| blueprint medicines corp | -32,045,000 |
| rapport therapeutics inc | -2,269,940 |
| nextcure inc | -1,059,200 |
| immatics n.v | -112 |
Affinity Asset Advisors, LLC got rid off the above stocks
Sector Distribution
Affinity Asset Advisors, LLC has about 75.4% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 75.4 |
| Others | 24.6 |
Market Cap. Distribution
Affinity Asset Advisors, LLC has about 9.1% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 38.9 |
| UNALLOCATED | 26 |
| SMALL-CAP | 17 |
| LARGE-CAP | 9.1 |
| MICRO-CAP | 7 |
| NANO-CAP | 2 |
Stocks belong to which Index?
About 39.9% of the stocks held by Affinity Asset Advisors, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 60.1 |
| RUSSELL 2000 | 39.9 |
Affinity Asset Advisors, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Affinity Asset Advisors, LLC
Affinity Asset Advisors, LLC has 82 stocks in it's portfolio. About 42.3% of the portfolio is in top 10 stocks. NRIX proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for Affinity Asset Advisors, LLC last quarter.
Last Reported on: 13 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 3.58 | 500,000 | 41,050,000 | added | 1.01 | ||
| AGLE | spyre therapeutics inc | 2.07 | 1,419,300 | 23,787,500 | added | 133 | ||
| AKBA | akebia therapeutics inc | 0.58 | 2,450,000 | 6,688,500 | added | 25.64 | ||
| ALKS | alkermes plc | 3.27 | 1,250,000 | 37,500,000 | added | 25.00 | ||
| ATXS | astria therapeutics inc | 0.19 | 300,000 | 2,184,000 | unchanged | 0.00 | ||
| AUTL | autolus therapeutics plc | 0.25 | 1,750,000 | 2,852,500 | reduced | -42.53 | ||
| AVTE | jade biosciences inc | 0.05 | 65,317 | 563,686 | unchanged | 0.00 | ||
| AVTX | avalo therapeutics inc | 1.11 | 1,006,220 | 12,789,000 | added | 65.53 | ||
| AXSM | axsome therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BBIO | bridgebio pharma inc | 0.29 | 65,000 | 3,376,100 | reduced | -56.67 | ||
| BPMC | blueprint medicines corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CELC | celcuity inc | 0.35 | 3,000,000 | 3,998,270 | new | |||
| CGEM | cullinan therapeutics inc | 0.14 | 263,817 | 1,564,440 | unchanged | 0.00 | ||
| CLDX | celldex therapeutics inc new | 0.68 | 300,000 | 7,761,000 | new | |||
| CMPS | compass pathways plc | 0.10 | 200,000 | 1,146,000 | new | |||
| CNTA | centessa pharmaceuticals plc | 2.34 | 1,107,160 | 26,848,700 | added | 23.00 | ||
| CNTX | context therapeutics inc | 0.03 | 402,653 | 390,090 | reduced | -22.27 | ||
| CRNX | crinetics pharmaceuticals in | 0.27 | 75,000 | 3,123,750 | reduced | -50.74 | ||
| CYTK | cytokinetics inc | 1.68 | 350,000 | 19,236,000 | new | |||
| ELYM | climb bio inc | 0.23 | 1,300,000 | 2,613,000 | reduced | -13.33 | ||